GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » Cash-to-Debt

HCW Biologics (HCW Biologics) Cash-to-Debt : 0.57 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. HCW Biologics's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.57.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, HCW Biologics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for HCW Biologics's Cash-to-Debt or its related term are showing as below:

HCWB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.57   Med: No Debt   Max: No Debt
Current: 0.57

During the past 5 years, HCW Biologics's highest Cash to Debt Ratio was No Debt. The lowest was 0.57. And the median was No Debt.

HCWB's Cash-to-Debt is ranked worse than
83.89% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs HCWB: 0.57

HCW Biologics Cash-to-Debt Historical Data

The historical data trend for HCW Biologics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

HCW Biologics Cash-to-Debt Chart

HCW Biologics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
No Debt No Debt No Debt 5.00 0.57

HCW Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.42 2.74 1.77 0.57

Competitive Comparison of HCW Biologics's Cash-to-Debt

For the Biotechnology subindustry, HCW Biologics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HCW Biologics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where HCW Biologics's Cash-to-Debt falls into.



HCW Biologics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

HCW Biologics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

HCW Biologics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HCW Biologics  (NAS:HCWB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


HCW Biologics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of HCW Biologics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


HCW Biologics (HCW Biologics) Business Description

Traded in Other Exchanges
N/A
Address
2929 N Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company believes age-related low-grade chronic inflammation is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong director, officer: Chief Executive Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam officer: Chief Financial Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers officer: SVP of Business Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene director C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao officer: VP of Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode officer: See Remarks C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd. 10 percent owner 16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057